argenx SE (ARGX) Stock Analysis
Range Bound setup · Temp Headwind edge
Healthcare · Biotechnology
Wait for pullback to $784.99. Weak momentum — blocks BUY_NOW at $802.24. Engine's entry $784.99 (Ma200 Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risk: Negative momentum.
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP),... Read more
Wait for pullback to $784.99. Weak momentum — blocks BUY_NOW at $802.24. Engine's entry $784.99 (Ma200 Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risk: Negative momentum. Chart setup: RSI 55 mid-range, Bollinger mid-band. Growth is cheap relative to earnings, but the chart hasn't confirmed yet (PEG 1.29, quality 9.0/10, growth 10.0/10). Score 6.7/10, high confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 63d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: moderate.
Recent Developments — argenx SE
Latest news
- ARGENX : Goldman Sachs keeps its Buy rating - marketscreener.com — marketscreener.com positive
- Is argenx SE (ARGX) Among the Most Promising Biotech Stocks to Buy? - Insider Monkey — Insider Monkey positive
- Is argenx SE (ARGX) Among the Most Promising Biotech Stocks to Buy? - Yahoo Finance — Yahoo Finance positive
- argenx SE at TD Cowen Healthcare Conference Transcript - GuruFocus — GuruFocus neutral
- Is It Time To Reassess argenx (ENXTBR:ARGX) After Recent Biotech Pipeline Headlines? - Yahoo Finance — Yahoo Finance neutral
Generated 2026-05-20T20:21:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker·2 ceiling hits
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $784.99. Weak momentum — blocks BUY_NOW at $802.24. Engine's entry $784.99 (Ma200 Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risk: Negative momentum. Chart setup: RSI 55 mid-range, Bollinger mid-band. Growth is cheap relative to earnings, but the chart hasn't confirmed yet (PEG 1.29, quality 9.0/10, growth 10.0/10). Target $920.41 (+14.7%), stop $732.77 (−9.5%), Setup A.R:R 2.4:1. Score 6.7/10, high confidence.
Take-profit target: $920.41 (+16.1% upside). Target $920.41 (+14.7%), stop $732.77 (−9.5%), Setup A.R:R 2.4:1. Stop-loss: $732.77.
Negative momentum.
argenx SE trades at a P/E of 35.4 (forward 21.8). TrendMatrix value score: 4.4/10. Verdict: Buy (Wait for Entry).
25 analysts cover ARGX with a consensus score of 4.2/5. Average price target: $1023.
What does argenx SE do?argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in...
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.